CA3180829A1 - Crystalline form of lnp023 - Google Patents
Crystalline form of lnp023Info
- Publication number
- CA3180829A1 CA3180829A1 CA3180829A CA3180829A CA3180829A1 CA 3180829 A1 CA3180829 A1 CA 3180829A1 CA 3180829 A CA3180829 A CA 3180829A CA 3180829 A CA3180829 A CA 3180829A CA 3180829 A1 CA3180829 A1 CA 3180829A1
- Authority
- CA
- Canada
- Prior art keywords
- lnp023
- hydrochloride
- hydrate form
- crystalline hydrate
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026637P | 2020-05-18 | 2020-05-18 | |
| US63/026,637 | 2020-05-18 | ||
| US202063052699P | 2020-07-16 | 2020-07-16 | |
| US63/052,699 | 2020-07-16 | ||
| PCT/IB2021/054225 WO2021234544A1 (en) | 2020-05-18 | 2021-05-17 | Crystalline form of lnp023 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180829A1 true CA3180829A1 (en) | 2021-11-25 |
Family
ID=76076387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180829A Pending CA3180829A1 (en) | 2020-05-18 | 2021-05-17 | Crystalline form of lnp023 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11603363B2 (https=) |
| EP (1) | EP4153580A1 (https=) |
| JP (3) | JP7592743B2 (https=) |
| KR (2) | KR20230009478A (https=) |
| CN (4) | CN120168469A (https=) |
| AU (2) | AU2021276912B2 (https=) |
| CA (1) | CA3180829A1 (https=) |
| IL (1) | IL297975A (https=) |
| TW (2) | TW202504893A (https=) |
| WO (1) | WO2021234544A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3675854T1 (sl) | 2017-08-31 | 2025-05-30 | Novartis Ag | Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3 |
| TW202504893A (zh) * | 2020-05-18 | 2025-02-01 | 瑞士商諾華公司 | Lnp023之結晶形式 |
| US11951101B2 (en) | 2020-07-16 | 2024-04-09 | Novartis Ag | Methods of using factor B inhibitors |
| WO2022143940A1 (zh) * | 2020-12-30 | 2022-07-07 | 南京明德新药研发有限公司 | 一系列哌啶取代的苯酸类化合物及其应用 |
| EP4333845A1 (en) * | 2021-05-07 | 2024-03-13 | Novartis AG | Iptacopan for the treatment of atypical hemolytic uremic syndrome |
| WO2022264101A1 (en) | 2021-06-18 | 2022-12-22 | Novartis Ag | Method of treating an autoimmune hematological disorder |
| CA3248808A1 (en) | 2022-03-04 | 2023-09-07 | Novartis Ag | USE OF IPTACOPAN FOR THE TREATMENT OF LUPUS NEPHROPATHY |
| JP7849520B2 (ja) * | 2022-06-30 | 2026-04-21 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 含窒素架橋複素環誘導体の薬学的に許容される塩、結晶形及びその調製方法 |
| EP4669321A1 (en) | 2023-02-23 | 2025-12-31 | Novartis AG | METHODS OF USING FACTOR B INHIBITORS |
| CN121712505A (zh) | 2023-08-25 | 2026-03-20 | 诺华股份有限公司 | 使用因子b抑制剂的方法 |
| WO2025148628A1 (zh) * | 2024-01-10 | 2025-07-17 | 河北以岭医药研究院有限公司 | 哌啶基吲哚衍生物及其制备方法和应用 |
| WO2025172910A1 (en) | 2024-02-16 | 2025-08-21 | Novartis Ag | Factor b inhibitors for treatment of anca-associated vasculitis |
| WO2026003809A1 (en) * | 2024-06-29 | 2026-01-02 | Assia Chemical Industries Ltd. | Solid state forms of iptacopan hydrochloride |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0301259D0 (en) | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
| KR20130086534A (ko) | 2010-06-01 | 2013-08-02 | 플러스 케미칼스, 에스.에이. | 익사베필론의 고체 형태 |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| MX2018007392A (es) | 2015-12-23 | 2018-08-15 | Greenovation Biotech Gmbh | Polipeptidos para inhibir la activacion del complemento. |
| SI3675854T1 (sl) | 2017-08-31 | 2025-05-30 | Novartis Ag | Derivati piperidinil-indola za uporabo v zdravljenju glomerulopatije c3 |
| TW202504893A (zh) * | 2020-05-18 | 2025-02-01 | 瑞士商諾華公司 | Lnp023之結晶形式 |
-
2021
- 2021-05-17 TW TW113137576A patent/TW202504893A/zh unknown
- 2021-05-17 JP JP2022557633A patent/JP7592743B2/ja active Active
- 2021-05-17 KR KR1020227043301A patent/KR20230009478A/ko active Pending
- 2021-05-17 CN CN202510350702.0A patent/CN120168469A/zh active Pending
- 2021-05-17 TW TW110117696A patent/TWI858258B/zh active
- 2021-05-17 CN CN202180035091.0A patent/CN115667240B/zh active Active
- 2021-05-17 US US17/322,409 patent/US11603363B2/en active Active
- 2021-05-17 WO PCT/IB2021/054225 patent/WO2021234544A1/en not_active Ceased
- 2021-05-17 EP EP21727571.8A patent/EP4153580A1/en active Pending
- 2021-05-17 IL IL297975A patent/IL297975A/en unknown
- 2021-05-17 CN CN202510371145.0A patent/CN120208923A/zh active Pending
- 2021-05-17 KR KR1020257009662A patent/KR20250048392A/ko active Pending
- 2021-05-17 AU AU2021276912A patent/AU2021276912B2/en active Active
- 2021-05-17 CA CA3180829A patent/CA3180829A1/en active Pending
- 2021-05-17 CN CN202510349446.3A patent/CN120172955A/zh active Pending
-
2023
- 2023-02-14 US US18/168,711 patent/US12384758B2/en active Active
-
2024
- 2024-03-13 AU AU2024201640A patent/AU2024201640B2/en active Active
- 2024-06-26 JP JP2024103249A patent/JP7789850B2/ja active Active
-
2025
- 2025-05-13 US US19/206,665 patent/US20250270186A1/en active Pending
- 2025-12-10 JP JP2025244399A patent/JP2026048795A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024150466A (ja) | 2024-10-23 |
| JP2026048795A (ja) | 2026-03-17 |
| JP7592743B2 (ja) | 2024-12-02 |
| AU2021276912B2 (en) | 2023-12-14 |
| CN120168469A (zh) | 2025-06-20 |
| WO2021234544A1 (en) | 2021-11-25 |
| AU2024201640B2 (en) | 2025-10-09 |
| KR20250048392A (ko) | 2025-04-08 |
| IL297975A (en) | 2023-01-01 |
| KR20230009478A (ko) | 2023-01-17 |
| CN120208923A (zh) | 2025-06-27 |
| TW202204335A (zh) | 2022-02-01 |
| TWI858258B (zh) | 2024-10-11 |
| US20230265067A1 (en) | 2023-08-24 |
| US11603363B2 (en) | 2023-03-14 |
| JP7789850B2 (ja) | 2025-12-22 |
| AU2021276912A1 (en) | 2022-11-24 |
| TW202504893A (zh) | 2025-02-01 |
| EP4153580A1 (en) | 2023-03-29 |
| AU2024201640A1 (en) | 2024-04-04 |
| CN115667240B (zh) | 2025-04-22 |
| CN120172955A (zh) | 2025-06-20 |
| JP2023518552A (ja) | 2023-05-02 |
| CN115667240A (zh) | 2023-01-31 |
| US20250270186A1 (en) | 2025-08-28 |
| US12384758B2 (en) | 2025-08-12 |
| US20210371394A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021276912B2 (en) | Crystalline form of LNP023 | |
| US20250188054A1 (en) | Crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
| EP3808742A1 (en) | Polymorph of selinexor | |
| US20220194936A1 (en) | Crystalline forms of n-(5-(5-((1r,2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide | |
| EP4359410A1 (en) | Crystalline form of sotorasib | |
| US12590095B2 (en) | Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor | |
| EP3887356B1 (en) | Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor | |
| RU2818684C1 (ru) | Кристаллическая форма lnp023 | |
| JP6594325B2 (ja) | 臭化チオトロピウムとラクトースの結晶形態 | |
| US9981912B2 (en) | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof | |
| WO2022263263A1 (en) | Crystalline form of avacopan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241025 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241225 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241225 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241225 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250422 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250422 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250422 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250423 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250618 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250618 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250618 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250618 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250618 |